This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Newey, P. J. Articles by Thakker, R. V. PubMed PubMed Citation Articles by Newey, P. J. Articles by Thakker, R. V. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology Endocrine Oncology

Asymptomatic Children with Multiple Endocrine Neoplasia Type 1 Mutations May Harbor Nonfunctioning Pancreatic Neuroendocrine Tumors

Academic Endocrine Unit (P.J.N., J.J., G.V.W., P.T.C., B.S., M.R.B., R.V.T.), Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom; Department of Radiology (R.R.P., F.V.G.), The Churchill Hospital, Oxford OX3 7LJ, United Kingdom; and Departments of Pathology (S.G.), Paediatric Surgery (P.R.V.J.), and Paediatric Endocrinology and Diabetes (F.J.R.), Oxford Children’s Hospital, Oxford OX3 9DU, United Kingdom

Address all correspondence and requests for reprints to: Professor R. V. Thakker, Academic Endocrine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford Centre for Diabetes, Endocrinology, and Metabolism (OCDEM), Churchill Hospital, Headington Oxford, OX3 7LJ, United Kingdom. E-mail: rajesh.thakker{at}ndm.ox.ac.uk.

Context: Multiple endocrine neoplasia type 1 (MEN1) is characterized by the occurrence of parathyroid, pituitary, and pancreatic tumors. MEN1, an autosomal dominant disorder, has a high degree of penetrance, such that more than 95% of patients develop clinical manifestations by the fifth decade, although this is lower at approximately 50% by age 20 yr. However, the lower penetrance in the younger group, which is based on detecting hormone-secreting tumors, may be an underestimate because patients may have nonfunctioning tumors and be asymptomatic.

Objective: The aim of the study was to evaluate the occurrence of nonfunctioning pancreatic neuroendocrine tumors in asymptomatic children with MEN1.

Patients: Twelve asymptomatic Northern European children, aged 6 to 16 yr, who were known to have MEN1 mutations were studied.

Results: Two asymptomatic children, who were aged 12 and 14 yr, had normal plasma fasting gastrointestinal hormones and were found to have nonfunctioning pancreatic neuroendocrine tumors that were more than 2 cm in size. Surgery and immunostaining revealed that the tumors did not have significant expression of gastrointestinal hormones but did contain chromogranin A and synaptophysin, features consistent with those of nonfunctioning pancreatic neuroendocrine tumors. The tumors had a loss of menin expression. The 14 yr old also had primary hyperparathyroidism and a microprolactinoma, and the 12 yr old had a nonfunctioning pituitary microadenoma. Three other children had primary hyperparathyroidism and a microprolactinoma.

Conclusion: Nonfunctioning pancreatic neuroendocrine tumors may occur in asymptomatic children with MEN1 mutations, and screening for such enteropancreatic tumors in MEN1 children should be considered earlier than the age of 20 yr, as is currently recommended by the international guidelines.